Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.
Liu LCY, Valente MAE, Postmus D, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, van der Meer P, Voors AA. Liu LCY, et al. Among authors: cleland jgf. Cardiovasc Drugs Ther. 2017 Jun;31(3):281-293. doi: 10.1007/s10557-017-6726-1. Cardiovasc Drugs Ther. 2017. PMID: 28656542 Free PMC article. Clinical Trial.
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Cleland JG, Goode K, Erhardt L, Remme WJ, Charlesworth A, Poole-Wilson PA, Di Lenarda A, Hanrath P, Komajda M, Metra M, Swedberg K, Torp-Pedersen C; Carvedilol or Metoprolol European Trial Investigators. Cleland JG, et al. Cardiovasc Drugs Ther. 2004 Mar;18(2):139-52. doi: 10.1023/B:CARD.0000029032.46744.56. Cardiovasc Drugs Ther. 2004. PMID: 15162076 Clinical Trial.
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Lutiger B, Scherhag A, Lukas MA, Charlesworth A, Poole-Wilson PA. Metra M, et al. Eur Heart J. 2005 Nov;26(21):2259-68. doi: 10.1093/eurheartj/ehi386. Epub 2005 Jul 21. Eur Heart J. 2005. PMID: 16040619 Clinical Trial.
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR, McMurray JJ, Bourge RC, Cleland JG, Cotter G, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, Torre-Amione G, Van Veldhuisen DJ, Frey A, Rainisio M, Kobrin I; VERITAS Investigators. Teerlink JR, et al. Am Heart J. 2005 Jul;150(1):46-53. doi: 10.1016/j.ahj.2005.04.035. Am Heart J. 2005. PMID: 16084150
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET).
Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, Di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA; COMET Investigators. Cleland JG, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1603-11. doi: 10.1016/j.jacc.2005.11.069. Epub 2006 Mar 29. J Am Coll Cardiol. 2006. PMID: 16630997 Free article. Clinical Trial.
723 results